Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on May 23, 2025
Tilray Medical bringt die bekannte kanadische Cannabismarke Good Supply nach Deutschland
GlobeNewswire
·
May 23, 2025
NEUMÜNSTER, Deutschland, May 23, 2025 (GLOBE NEWSWIRE) -- Tilray Medical („Tilray“), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und ein weltweit führendes Unternehmen im Bereich des medizinischen Cannabis, das die …
Tilray Medical introduit Good Supply, la marque emblématique de cannabis canadienne, en Allemagne
GlobeNewswire
·
May 23, 2025
NEUMÜNSTER, Allemagne, 23 mai 2025 (GLOBE NEWSWIRE) -- Tilray Medical (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux patients et aux professionnels de santé de …
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire
·
May 23, 2025
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing …
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
GlobeNewswire
·
May 23, 2025
Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy Platform Abstract published on podium presentation that will take place during the “Developmental …
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
May 23, 2025
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
Dr. Mohana Rao (Dr. Rao) Redefines Indian Neurosurgery: Economic Times Spotlights Guntur's Global Brain and Spine Leader
EIN Presswire
·
May 23, 2025
India’s First BrainPath Surgery to the Nation’s Only Hybrid Neurosurgical OR of its kind, Dr. Patibandla (Dr Rao) Puts Guntur on the Map — The Economic Times GUNTUR, ANDHRA PRADESH, INDIA, May 23, 2025 /EINPresswire.com/ -- Dr. Rao’s Hospital in Guntur …
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 23, 2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies …
Safe Shot to Capitalize on Yerbae’s Strong Retail Presence & Distributor Network Following Acquisition
GlobeNewswire
·
May 23, 2025
Acquisition expected to increase Safety Shot annual revenue by 1000 percent over 2024 SCOTTSDALE, Ariz., May 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, …
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
May 23, 2025
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, …
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
GlobeNewswire
·
May 23, 2025
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice …
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
GlobeNewswire
·
May 23, 2025
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an …
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
GlobeNewswire
·
May 23, 2025
ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two …